

IN THE SPECIFICATION

Kindly enter these paragraphs.

Page 16, replace the first paragraph starting at line 1 with the following:

Figure 2 shows (Fig. 2A [[1]]) the chromosomal positions of avermectin aglycon synthase genes and the domain sequences of synthase units, (Fig. 2B [[2]]) the estimated steps of synthesizing avermectin aglycon, and (Fig. 2C [[3]]) the structure of 6,8a-seco-6,8a-deoxy-5-oxoAvermectin aglycon synthesized with polyketide synthases, which are the gene products of avermectin aglycon synthase genes aveAI and aveAII, and the positions of lower fatty acids which are incorporated into the skeleton of the compound. In this figure, SU indicates synthase unit, ACP indicates acyl carrier protein, AT indicates an acyltransferase, DH indicates dehydratase, DH* indicates a dehydratase-like domain which is estimated to be inactive, KR indicates β -ketoacyl-ACP reductase, KR* indicates a β -ketoacyl-ACP reductase-like domain which is estimated to be active but is not reflected in the polyketide synthetic reaction, KS indicates β -ketoacyl-ACP synthase, and TE indicates thioesterase.

Pages 47-48, replace the fifth paragraph starting on line 31 with the following:

The information of avermectin aglycon synthase genes (SEQ ID NOs:1 and 2) derived from the avermectin-producing strain, which were obtained and sequenced in Example 1, indicated that avermectin was biosynthesized through the biosynthetic pathway shown in Figures 2A-2C.

Entry and approval of the corrected formal drawings are requested.